We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


29 January 2004 By Robert Cyran

The firm has worked for both drugs makers in the past. So its absence in a hostile fight is puzzling. Lazard s strong relationship to Pfizer may offer an explanation. The company makes a surprisingly strong candidate for a white knight.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)